This article explains prior authorization mechanics and appeal rights using 2024 federal data; it is educational, not legal or medical advice, and coverage rules vary by plan and state.
TL;DR — Quick Verdict
- Medicare Advantage insurers issued nearly 53 million prior authorization determinations in 2024 and denied 4.1 million of them — a 7.7% denial rate, per KFF analysis of CMS data.
- Appeals work: 80.7% of appealed Medicare Advantage denials were partially or fully overturned in 2024, yet only 11.5% of denials were ever appealed.
- ACA marketplace plans denied 19% of in-network claims in 2024, but fewer than 1% of those denials were appealed by consumers.
- Federal deadlines are tight: you have 180 days to file an internal appeal and 4 months after a final denial to request an independent external review.
- Comparison result: appealing costs you time and postage; not appealing costs you the full price of the service — often thousands of dollars for imaging, surgery, or specialty drugs.
- Recommendation: appeal every medically necessary denial in writing, request the plan’s specific denial reason, and escalate to external review if the internal appeal fails.
In 2024, insurers running Medicare Advantage plans made nearly 53 million prior authorization determinations — and denied 4.1 million of them, according to a KFF analysis of federal CMS data. Here is the number that should change your behavior: of the denials that were appealed, 80.7% were partially or fully overturned. Yet patients appealed just 11.5% of the time. The overwhelming majority of people who received a “no” simply accepted it, even though four out of five who pushed back won.
Prior authorization is the approval an insurer — UnitedHealthcare, Humana, Aetna, Cigna, or your ACA marketplace carrier — requires before it will pay for a test, procedure, or drug. When that approval is denied, the bill can land squarely on you. This guide breaks down how the process actually works, what the federal timelines are, what a denial costs versus what an appeal costs, the mistakes that sink otherwise winnable appeals, and exactly how to respond when you get denied. Every figure here is drawn from primary federal sources including CMS and KFF, and every deadline reflects current 2026 rules.
What Prior Authorization Actually Costs You in Denials
Prior authorization is not rare, and denials are not trivial. The scale is enormous: Medicare Advantage plans alone processed almost 53 million determinations in 2024, averaging 1.7 requests per enrollee. When a request is denied and you proceed with care anyway, the insurer’s share of the cost disappears — you owe the full billed amount.
The stakes vary sharply by coverage type. Traditional Medicare rarely uses prior authorization, but where it does, the denial rate is strikingly high. The table below shows how denial exposure differs across the major coverage categories, all from 2024 federal data.
Source: KFF analysis of CMS data, published 2026 (verify at kff.org). ACA overturn figure reflects that insurers upheld 66% of appealed denials, leaving roughly one-third reversed.
Note the pattern the data exposes. Where appeals are common and escalate to independent reviewers, as in Medicare Advantage, overturn rates soar past 80%. Where consumers almost never appeal, as in the ACA marketplace’s sub-1% rate, insurers uphold two-thirds of their original decisions. The difference between winning and losing is often just whether you file. If you are weighing plans by denial exposure, the trade-offs surface most clearly when you look at HMO vs PPO vs HDHP total annual cost comparison.
How the Prior Authorization Process Works, Step by Step
Consider a real-world scenario. Your orthopedist orders an MRI for a torn rotator cuff. Before the imaging center will schedule you, it submits a prior authorization request to your insurer, attaching your physician’s clinical notes. The insurer’s reviewer — increasingly an algorithm applying criteria sets like InterQual or MCG — checks whether the documentation matches its medical-necessity rules.
Three outcomes are possible. The request is approved, and you proceed. It is denied in full, meaning the insurer will not cover the MRI at all — this happened in 73% of Medicare Advantage denials in 2024. Or it is partially approved, where the insurer authorizes some but not all of what was requested, such as approving 10 of 14 ordered physical therapy sessions.
Timing is now federally regulated. Under the CMS Interoperability and Prior Authorization final rule (CMS-0057-F), impacted payers must return prior authorization decisions within 72 hours for expedited urgent requests and seven calendar days for standard non-urgent requests. The clock starts when the payer receives the request with all required documentation. Beginning in 2026, those same payers must state a specific reason for every non-drug denial — a change that directly strengthens your ability to respond, because a vague denial is far harder to fight than a specific one.
What determines whether you get approved often has less to do with whether the care is necessary and more to do with whether the paperwork speaks the insurer’s language. A physician’s note that clearly supports treatment under standard-of-care guidelines may still be denied if it lacks the specific keywords or clinical thresholds the plan’s review algorithm is programmed to find. That gap — a documentation-format denial rather than a genuine clinical disagreement — is exactly why so many denials collapse on appeal.
Appealing vs. Accepting the Denial: Which Is Better for Your Wallet?
Accepting a denial feels like the path of least resistance. It is almost always the more expensive one. Weigh the two options directly.
Accepting the denial costs you the full price of the service. An out-of-network specialist visit, an advanced imaging study, or a specialty drug can run from several hundred to many thousands of dollars once the insurer’s contribution vanishes. You also lose the care itself, or delay it — and delay carries its own health cost.
Appealing costs you time, documentation, and postage or a portal upload. The internal appeal is free. If it fails, the external review by an independent organization is also provided at no charge to you under federal ACA rules. The expected value math is lopsided: in Medicare Advantage, an appeal carried an 80.7% chance of a partial or full reversal in 2024. Even in the ACA marketplace, where insurers uphold about two-thirds of appealed denials, roughly one in three appeals still succeeds — against a near-zero cost to file.
Verdict
For any denial of medically necessary care, appeal. The cost of appealing is your time; the cost of accepting is the full bill plus the lost or delayed treatment. With 80.7% of Medicare Advantage appeals overturned and external review free under federal law, the risk-adjusted math favors filing in nearly every case. Accept a denial only when you genuinely do not want or need the service.
The one caveat: if the denied service is inexpensive and you would not pursue it regardless, the appeal effort may not be worth it. But for imaging, surgery, hospital stays, and specialty medications, the calculus overwhelmingly favors fighting back. Understanding your deductible and out-of-pocket maximum mechanics helps you see exactly how much a covered versus denied service moves your annual total.
The Denial-Response Timeline: Federal Deadlines You Cannot Miss
Deadlines are where winnable appeals die. Federal rules under the Affordable Care Act give you specific windows, and missing them can forfeit your rights regardless of how strong your case is. The sequence below applies to non-grandfathered plans nationwide.
Source: HealthCare.gov and CMS Center for Consumer Information and Insurance Oversight (verify at healthcare.gov). State windows may differ; some states allow longer or shorter external-review filing periods.
Two details matter enormously. First, in an urgent situation you can request the external review at the same time as your internal appeal, rather than waiting for the internal process to finish. Second, the federal external review is handled by an independent review organization — for HHS-administered cases, MAXIMUS Federal Services — whose decision is binding on the insurer. If the reviewer overturns the denial, your plan must cover the service.
What Most People Get Wrong About Fighting Denials
The 80.7% overturn rate proves most denials are beatable. These are the specific mistakes that keep people from winning.
Mistake one: not appealing at all. Only 11.5% of Medicare Advantage denials and under 1% of ACA marketplace denials were appealed in 2024. The consequence is paying full price for care that was often medically justified. The correct action is simple: appeal every denial of care you actually need, because the base rates favor you dramatically.
Mistake two: ignoring the stated denial reason. Many denials are documentation-format problems, not clinical rejections. The consequence of ignoring the reason is resubmitting the same insufficient paperwork and getting denied again. The correct action is to read the specific denial reason — which non-drug denials must now include as of 2026 — and address exactly that gap, whether it is a missing chart note or an absent clinical threshold.
Mistake three: missing the deadline. Waiting past the 180-day internal-appeal window or the 4-month external-review window forfeits your rights entirely. The consequence is a permanent loss regardless of case strength. The correct action is to calendar both deadlines the day your denial arrives.
Mistake four: skipping the physician’s letter. A denial appeal with no supporting statement from the treating doctor is far weaker. The consequence is that the reviewer sees only the insurer’s version. The correct action is to request a letter of medical necessity citing the relevant clinical guidelines and attach it to your appeal.
Mistake five: stopping after the internal appeal. Insurers upheld 66% of appealed ACA denials internally — but external review is a separate, independent stage. The consequence of stopping is leaving the free, binding external review on the table. The correct action is to escalate to an independent review organization when the internal appeal fails. If your denial stems from care outside your network, the mechanics in the real costs of going out of network explain why the exposure runs so high.
Who Should Prioritize Appeals — and Is It Always Worth It?
Not every denial demands the same energy, so apply conditional logic. If the denied service is high-cost — advanced imaging, surgery, a hospital admission, post-acute rehab, or a specialty drug — appeal without hesitation. Post-acute care denials in Medicare Advantage have been overturned on appeal at rates reaching 95% for skilled nursing facilities, meaning these denials are frequently reversed once challenged.
If you manage a chronic condition, prior authorization is a recurring cost of care, and a systematic appeal habit pays off repeatedly across the year. Plan selection matters just as much here; the trade-offs in plan selection with a chronic condition can reduce how often you hit authorization walls in the first place.
If the denial is for a low-cost service you are ambivalent about, the effort may exceed the payoff — this is the narrow case where accepting the denial is rational. But that ceiling is low. Given that internal appeals are free and external reviews cost nothing, the threshold for “worth it” sits at roughly the price of a specialist copay’s worth of your time.
One structural shift is worth tracking. Traditional Medicare, historically almost free of prior authorization, launched the WISeR model on January 15, 2026, requiring prior authorization for select services in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington through 2031. If you have Original Medicare in those states, prior authorization is now part of your landscape too, and the same appeal rights apply. Anyone comparing coverage before age 65 should factor these mechanics into coverage options for early retirees under 65, and those weighing a job change should review how appeals carry over in COBRA vs marketplace coverage after job loss.
Frequently Asked Questions
How long does an insurer have to decide a prior authorization request?
Under the CMS Interoperability and Prior Authorization final rule (CMS-0057-F), impacted payers must decide expedited urgent requests within 72 hours and standard requests within seven calendar days. The clock begins when the payer receives your request with all required documentation. These timeframes apply to Medicare Advantage, Medicaid, CHIP, and certain marketplace plans.
What are my odds of winning an appeal?
Strong, if you file. In Medicare Advantage, 80.7% of appealed denials were partially or fully overturned in 2024, according to KFF’s analysis of CMS data. In the ACA marketplace, insurers upheld about 66% of appeals, meaning roughly one in three succeeded internally — before the separate, free external review stage that can reverse the rest.
Does the appeal cost me money?
No. The internal appeal is free, and under Affordable Care Act rules the external review by an independent review organization is also provided at no cost to you. Your only investment is time, documentation, and a physician’s letter of medical necessity. Compared with paying the full price of a denied service, appealing is nearly always the cheaper path.
What happens if I miss the appeal deadline?
You generally forfeit your right to appeal. Federal rules give you 180 days from the denial notice to file an internal appeal and four months from a final internal denial to request external review. Some states set different windows. Calendar both deadlines the day your denial arrives, because a strong case filed late is usually dismissed.
Why do so few people appeal if the success rate is high?
Awareness and effort. In 2024 just 11.5% of Medicare Advantage denials and under 1% of ACA marketplace denials were appealed, per KFF. Many people do not know external review is free and binding, assume a denial is final, or find the paperwork daunting. That gap between the low appeal rate and the high overturn rate is the core opportunity this guide highlights.
How We Researched This Article
This analysis draws exclusively on primary federal sources and the health-policy research organization KFF, which analyzes raw CMS data. Prior authorization volume, denial, appeal, and overturn figures for Medicare Advantage and traditional Medicare come from KFF’s analysis of federal CMS prior authorization data covering calendar year 2024, published in early 2026. Figures cited include nearly 53 million determinations, 4.1 million denials (a 7.7% rate), an 11.5% appeal rate, and an 80.7% overturn rate.
ACA marketplace denial figures — 19% of in-network claims, 37% of out-of-network claims, a sub-1% appeal rate, and a 66% uphold rate — come from KFF’s analysis of CMS Transparency in Coverage data for HealthCare.gov qualified health plans in 2024. Readers can review the underlying briefs at KFF’s prior authorization research hub and KFF’s 2024 ACA marketplace claims denials brief.
Regulatory timeframes and denial-reason requirements come directly from the CMS Interoperability and Prior Authorization final rule (CMS-0057-F), available at the CMS-0057-F fact sheet. Consumer appeal deadlines and the external review process are drawn from HealthCare.gov’s appeals guidance and CMS’s Center for Consumer Information and Insurance Oversight. WISeR model details reflect CMS Innovation Center announcements and KFF’s February 2026 model analysis.
These figures are measured administrative data reported by payers to CMS, not modeled estimates, though appeal-outcome shares reflect only the small minority of denials that were appealed and may not represent all denials. State-level appeal windows and coverage rules vary and were not individually surveyed here. This research reflects data available as of publication in 2026. All figures were verified against named primary sources before publication.